Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ: SNGX )

2.300 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Soligenix, Inc. - Common Stock

< Previous 1 2 Next >
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Via Investor Brand Network
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Soligenix Aims To Push The Boundaries In Treating Rare Diseases
Via TheNewswire.com
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
By Kyle Anthony, Benzinga 
Via TheNewswire.com
Soligenix Announces Participation at the Spartan Capital Investor Conference
Premier Event to Showcase Growth Companies and Foster High-Level Investor Engagement 
Via TheNewswire.com
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026
By Kyle Anthony, Benzinga 
Via TheNewswire.com
Exposures COVID-19
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
Soligenix Announces Participation at the Spartan Capital Investor Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Uncover Why This Pharma Stock Jumped 400% on Study Update
Shares of Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, surged almost 400% today after announcing positive data. 
Via MarketBeat
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
ASP Isotopes and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Via ACCESSWIRE
SPI Energy and Soligenix Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Via ACCESSWIRE
Knightscope, Soligenix, and Genetic Technologies Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Via ACCESSWIRE
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
Via ACCESSWIRE
Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Soligenix, and Graphex Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
Via ACCESSWIRE
Soligenix (NASDAQ: SNGX) Reports Strong Clinical Results from Compatibility Study of HyBryte as a Treatment for Cutaneous T-Cell Lymphoma
Soligenix, Inc. (NASDAQ: SNGX) is engaged as a late-stage biopharmaceutical company that is focused on the research, development and commercialization 
Via Spotlight Growth
Exposures Product Safety
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:NNOX),(NASDAQ:SNGX),(NASDAQ:CRDF) EQNX::TICKER_END 
Via FinancialNewsMedia
Soligenix, Inc: Vital Vaccine Development Program has Potential to Address Future Marburg Virus Outbreaks
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Death
Exposures Death
Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Soligenix Delivers Two Pivotal Milestones
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Soligenix Positioned for Growth: Late-stage Pipeline and Key Q4 Milestones
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
UPDATE: Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat with PCG Advisory
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.